Phase I/Ib study of carfilzomib and panobinostat with or without dexamethasone in patients with relapsed/refractory multiple myeloma

Affiliations

• ¹ Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX eemanasanch@mdanderson.org.
• ² Karyopharm Therapeutics, Newton, MA.
• ³ Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
• ⁴ Department of Diagnostic Radiology, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX.
• ⁵ Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.
• ⁶ Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.